Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
- PBYI reported a narrower adjusted loss in Q1 of 2024. - Q1 total revenues were $43.8 million, beating estimates. - Product revenues from Nerlynx were $40.3 million. - PBYI expects Nerlynx product sales to be $183-$190 million in 2024. - PBYI in-licensed alisertib for clinical development. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis